Biopharma news, November 15, 2026
The most important drug and company news of November 15, 2026, ranked, each linked to its Gosset profiles.
Pivotal readout
Mazdutide Gains China Reimbursement
Innovent says mazdutide has been included in China's 2026 national reimbursement drug list for glycemic control in adults with type 2 diabetes, with the revised list effective January 1, 2027. The company cites DREAMS phase 3 trials showing glycemic and weight benefits, including a 48% composite response rate in DREAMS-3 versus 21% with semaglutide. In obesity studies, mazdutide was associated with weight reductions of 14.84% at 48 weeks in GLORY-1 and 20.1% at 60 weeks in GLORY-2.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Clinical readout
OJEMDA Four-Year FIREFLY-1 Results
In the four-year exploratory FIREFLY-1 analysis, median time to next treatment was 50.9 months among 76 efficacy-evaluable patients. Of 41 patients entering post-treatment observation, 76% remained treatment-free for at least 12 months and 54% for at least 24 months; 54% experienced tumor rebound. The safety profile remained consistent with prior findings; grade 3 or higher treatment-related reduced growth velocity occurred in 36% of 137 safety-evaluable patients.
Source types: Press release. Sources are available to Gosset users. Log in to see them.